List of Excipients in Branded Drug SUSTOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Heron Therapeutics Inc	SUSTOL	granisetron	47426-101	POLYETHYLENE GLYCOL MONOMETHYL ETHER 550	1969-12-31

Sustol Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Sustol is an extended-release subcutaneous formulation of granisetron hydrochloride developed by Heron Therapeutics for chemotherapy-induced nausea and vomiting. Its commercial value is tied less to granisetron itself, which is an established generic molecule, than to the depot-delivery system, injection convenience, dosing persistence, and formulation know-how.

The strongest opportunity is a reformulated or licensed long-acting granisetron product that preserves Sustol's pharmacokinetic advantages while reducing injection volume, excipient burden, manufacturing complexity, and administration friction.

What is Sustol and how does its formulation work?

Sustol, also known as APF530, is a single-dose extended-release granisetron injection administered subcutaneously before chemotherapy. The product was approved by the U.S. Food and Drug Administration in 2016 under NDA 206286 for prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy and delayed nausea and vomiting associated with highly emetogenic chemotherapy.[1]

Unlike conventional intravenous or immediate-release oral granisetron, Sustol uses a biodegradable polymer-based depot system. The formulation releases granisetron over multiple days after subcutaneous administration. The delivery platform was developed to maintain therapeutic drug exposure through the delayed phase of chemotherapy-induced nausea and vomiting.

Attribute	Sustol
Active ingredient	Granisetron hydrochloride
Therapeutic class	5-HT3 receptor antagonist
Dosage form	Extended-release subcutaneous injection
Administration	Single subcutaneous dose before chemotherapy
Approved indication	Chemotherapy-induced nausea and vomiting
NDA	206286
Developer	Heron Therapeutics
Delivery technology	Biodegradable polymer depot
Primary commercial differentiator	Extended duration from one injection

Sustol is not a biologic. Biosimilar competition is therefore irrelevant. The principal competitive threats are generic granisetron tablets, conventional injectable granisetron, palonosetron, fosnetupitant/palonosetron products, and newer antiemetic combinations.

What excipients are used in Sustol?

Sustol's commercial and technical differentiation depends on its excipient system rather than on granisetron. Public prescribing information identifies the product as a polymer-based extended-release injection. The formulation uses a proprietary biodegradable delivery matrix and organic excipient components required to solubilize, stabilize, and control release of the active ingredient.[1]

Public information should be separated into three categories:

1. Excipients disclosed in the FDA-approved product labeling.
2. Platform polymers and solvent systems described in Heron and predecessor-company patent filings.
3. Manufacturing-process excipients and processing aids that may not be fully disclosed in commercial-facing materials.

Heron's Biochronomer platform has been described in patent literature as a biodegradable polymer depot system capable of controlled drug release after subcutaneous administration.[2] The platform's commercial value may reside in the combination of polymer composition, drug loading, molecular-weight control, solvent selection, water ingress, polymer degradation, and injection behavior.

Excipient functions in a Sustol-type formulation

Excipient or excipient class	Functional role	Commercial significance
Biodegradable polymer	Controls depot formation and drug release	Core platform differentiator
Organic solvent or plasticizing system	Maintains injectability and polymer solubility	Affects viscosity, tolerability, and scale-up
Buffer or pH-control component	Supports granisetron stability	May affect precipitation and depot performance
Tonicity modifier	Supports local tolerability	Important for subcutaneous administration
Antioxidant or stabilizer	Limits chemical degradation	Relevant to shelf life and container compatibility
Preservative, if used	Controls microbial risk in multidose or manufacturing settings	Must be balanced against local tissue tolerance

A replacement product should not assume that the original excipient system is optimal. A modern development program could target lower viscosity, lower injection force, reduced local irritation, simpler aseptic processing, and improved compatibility with prefilled syringes.

What excipient strategy is strongest for a Sustol successor?

The strongest strategy is a platform-preserving reformulation rather than a conventional granisetron generic. A direct generic would compete primarily on price and would lose Sustol's principal differentiation.

1. Reduce injection burden

Subcutaneous depot products face practical limits on injection volume and force. A successor could improve usability through:

• Higher granisetron concentration.
• Lower-viscosity polymer precursors.
• A more efficient solvent or plasticizer system.
• A smaller needle gauge without excessive injection force.
• A prefilled syringe or autoinjector-compatible presentation.

A smaller-volume product could be attractive in outpatient oncology clinics, where nursing time and patient acceptance affect product selection.

2. Improve local tolerability

Depot formulations can produce pain, induration, erythema, nodules, or delayed local reactions. The excipient program should evaluate:

• Polymer degradation products.
• Solvent tissue compatibility.
• Osmolality.
• pH.
• Injection volume.
• Depot geometry.
• Drug crystallization at the injection site.

Reducing local reactions could support formulary adoption even if the product has a higher acquisition price than generic granisetron.

3. Expand release duration

Sustol's value comes from coverage of delayed chemotherapy-induced nausea and vomiting. A successor could seek a controlled-release window of three to five days, subject to clinical and regulatory validation. Excessive duration could create a disadvantage if adverse events occur or if chemotherapy regimens change rapidly.

The release profile must be matched to chemotherapy timing. A product that releases too slowly may underperform during the acute phase. A product that releases too quickly may lose the economic benefit of long-acting dosing.

4. Improve manufacturability

The commercial risk in polymer depots often lies in process reproducibility. Development work should focus on:

• Polymer molecular-weight distribution.
• Drug loading uniformity.
• Water content.
• Residual solvent control.
• Syringeability over shelf life.
• Sterile filtration or terminal sterilization feasibility.
• Container-closure compatibility.
• Batch-to-batch release testing.

A formulation with a less sophisticated polymer but a more robust manufacturing process may have greater commercial value than a technically superior formulation with difficult scale-up.

What formulation patents protect Sustol-type products?

Sustol-related protection is likely distributed across several claim categories rather than a single composition-of-matter patent. Relevant patent families may cover:

• Granisetron-containing biodegradable depots.
• Polymer composition and degradation chemistry.
• Drug-to-polymer ratios.
• Solvent and plasticizer combinations.
• Subcutaneous administration.
• Treatment of chemotherapy-induced nausea and vomiting.
• Specific pharmacokinetic profiles.
• Manufacturing methods and depot preparation.

The strategic value of each category differs. A broad polymer-composition claim can block competing products even when the competitor changes granisetron concentration. A narrow method-of-use claim may provide less commercial leverage if a rival launches a different long-acting antiemetic formulation.

FDA Orange Book listings, patent term adjustments, terminal disclaimers, and any patent-use-code information should be reviewed before relying on a Sustol patent as a freedom-to-operate barrier.[3] Patent status should not be inferred from the original approval date. Patent families can have different expiration dates, continuations, prosecution histories, and geographic coverage.

When does Sustol lose exclusivity?

Sustol's small-molecule active ingredient does not receive biologic exclusivity. Its commercial protection depends on regulatory exclusivity, formulation and method-of-use patents, trade secrets, manufacturing know-how, and market access.

Protection category	Relevance to Sustol
New chemical entity exclusivity	Generally unavailable because granisetron was previously approved
New clinical investigation exclusivity	May apply to qualifying clinical studies, subject to FDA determination
Orphan exclusivity	Not expected for the approved CINV indication
Formulation patents	Potentially important
Method-of-use patents	Potentially important
Manufacturing patents	Relevant to platform and scale-up
Trade secrets	Important for polymer synthesis and process controls
Biosimilar exclusivity	Not applicable

A generic applicant could pursue an abbreviated new drug application for immediate-release granisetron, but that would not automatically establish substitutability for an extended-release subcutaneous product. A Sustol-equivalent product would likely require a product-specific regulatory pathway and comparative evidence addressing release, exposure, local tolerability, and clinical performance.

What Paragraph IV challenges and litigation affect Sustol?

A Paragraph IV challenge would be relevant only to listed patents and only if a generic applicant sought approval for a product that FDA regarded as pharmaceutically and therapeutically equivalent to the listed product. Conventional granisetron generics do not necessarily create a direct Sustol patent challenge because they use a different dosage form and release profile.

The principal litigation risks are therefore formulation-specific:

• A generic or specialty pharmaceutical company could challenge polymer, solvent, or method-of-use patents.
• The sponsor could assert infringement based on depot composition or pharmacokinetic claims.
• A competitor could design around the polymer while retaining the same active ingredient and therapeutic objective.
• Patent litigation could focus on claim construction for biodegradable polymer systems and controlled-release parameters.

Public FDA and court records should be checked for current Paragraph IV notices, ANDA litigation, patent-listing disputes, and any settlement agreements. No settlement should be treated as commercially relevant unless it establishes an authorized generic, launch date, license, or geographic restriction.

What is Sustol's FDA and Orange Book status?

Sustol received FDA approval under NDA 206286. FDA labeling and the Drugs@FDA database are the primary sources for approval history, product labeling, supplements, and regulatory status.[1]

The Orange Book is the controlling source for current listed patents and exclusivity information.[3] A product may remain approved while being commercially unavailable. That distinction matters for licensing, relaunch, and regulatory strategy.

A buyer or licensee should separately assess:

• Whether the NDA is active.
• Whether the product is listed as currently marketed.
• Whether the sponsor has reported discontinuation.
• Whether listed patents remain enforceable.
• Whether any patents have expired or been delisted.
• Whether a supplemental approval is required for a new presentation.
• Whether the original manufacturing site remains qualified.

What commercial opportunities exist for Sustol?

Relaunch or regional licensing

The most direct opportunity is acquisition or licensing of Sustol rights in territories where the NDA, manufacturing package, and clinical dossier retain value. A relaunch would require a credible supply plan and a positioning strategy against low-cost generic granisetron.

Potential licensees include:

• Specialty oncology companies.
• Hospital injectable manufacturers.
• Contract development and manufacturing organizations.
• Regional pharmaceutical companies with oncology sales forces.
• Companies selling antiemetic combination regimens.

Reformulated long-acting granisetron

A new formulation could be positioned around:

• Lower injection volume.
• Lower injection pain.
• Improved prefilled-syringe usability.
• Longer or more predictable delayed-phase coverage.
• Reduced cold-chain requirements.
• Easier clinic administration.
• Compatibility with combination antiemetic protocols.

A reformulation would need to avoid infringement of active formulation claims and would likely require a new regulatory submission rather than a simple generic application.

Combination antiemetic products

Granisetron could be combined commercially, rather than physically in one formulation, with agents such as dexamethasone, an NK1 receptor antagonist, olanzapine, or a novel supportive-care therapy. The opportunity is strongest in regimens where clinicians prefer fewer administration steps.

A fixed-dose combination would face formulation, compatibility, dosing, and regulatory complexity. A co-pack or coordinated dosing kit may offer a lower-risk commercial path.

Non-oncology applications

Long-acting 5-HT3 delivery could have potential in other nausea and vomiting settings, but these uses would require clinical development and may face strong competition from inexpensive oral and injectable products. The economic case is weaker unless the depot provides a meaningful adherence or care-setting advantage.

How strong is the Sustol patent estate?

The patent estate is potentially valuable but technically vulnerable to design-around strategies. Polymer-depot patents can be strong when they claim a broad platform and narrow release parameters that competitors cannot easily avoid. They are weaker when claims depend on specific excipients, narrow concentration ranges, or limited pharmacokinetic windows.

Strength factor	Assessment
Active ingredient protection	Weak, because granisetron is established
Delivery-system protection	Potentially strong
Formulation design-around risk	Moderate to high
Manufacturing know-how	Potentially high value
Method-of-use protection	Dependent on claim scope and listing
Biosimilar barrier	None
Generic substitution barrier	Meaningful if dosage form differs
Commercial durability	Dependent on current listing and market availability

The most defensible asset may be the integrated formulation and manufacturing package rather than any single patent. Polymer synthesis, residual-solvent control, injection performance, and release testing can create practical barriers that are difficult to replicate quickly.

What generic launch risks exist?

A conventional granisetron generic can compete with Sustol on price without duplicating its delivery system. It may pressure formulary budgets and weaken the perceived need for a premium long-acting product.

A true Sustol-equivalent launch would face greater barriers:

1. Demonstrating equivalent extended-release performance.
2. Matching local tolerability.
3. Establishing a reliable sterile manufacturing process.
4. Addressing patent claims.
5. Securing oncology-clinic adoption.
6. Demonstrating economic value against combination antiemetic products.

The highest-risk scenario for a Sustol relaunch is not necessarily a direct generic. It is a market in which clinicians use inexpensive generic granisetron plus other antiemetics and do not assign sufficient value to one long-acting injection.

Key Takeaways

• Sustol's value lies in its polymer-based extended-release delivery system, not in granisetron exclusivity.
• The best commercial opportunity is a lower-volume, lower-viscosity, better-tolerated long-acting granisetron formulation.
• Excipient selection should prioritize local tolerability, syringeability, polymer reproducibility, residual-solvent control, and release consistency.
• Conventional granisetron generics are competitive substitutes but are not necessarily direct Sustol equivalents.
• Patent value is concentrated in depot composition, formulation ranges, release profiles, manufacturing processes, and method-of-use claims.
• Biosimilar risk does not apply.
• A relaunch or licensing deal would depend on active NDA status, current Orange Book listings, manufacturing readiness, and reimbursement positioning.
• The strongest defensibility may come from combined patent rights and manufacturing trade secrets.

FAQs

Can Sustol be replaced by generic granisetron?

Generic granisetron can provide the same active ingredient but generally does not reproduce Sustol's extended-release subcutaneous delivery. Substitution depends on dosage form, clinical protocol, and institutional formulary rules.

Which excipient is most important in Sustol?

The biodegradable polymer depot is the central excipient technology because it controls drug release. Solvent and plasticizer selection also affects injection force, local tolerability, stability, and manufacturing.

Is Sustol eligible for biosimilar competition?

No. Sustol contains a chemically synthesized small molecule, granisetron hydrochloride. Competition would arise through generic, hybrid, or reformulated-drug pathways rather than the biosimilar pathway.

Could Sustol be reformulated into a prefilled syringe?

Potentially, but the polymer viscosity, injection force, syringe materials, needle dimensions, stability, and container-closure system would require separate development and regulatory assessment.

What is the main barrier to commercializing a Sustol follow-on?

The main barrier is demonstrating that a new depot formulation provides reliable extended release with acceptable subcutaneous tolerability while achieving a cost and convenience advantage over generic granisetron and competing antiemetic combinations.

References

1. U.S. Food and Drug Administration. (2016). Sustol (granisetron) extended-release injection, prescribing information. FDA Drugs@FDA.

2. Heron Therapeutics, Inc. (Various years). Patents and patent applications relating to Biochronomer polymer-based drug-delivery systems and granisetron extended-release formulations. U.S. Patent and Trademark Office.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.